Mentor ‘looking to make acquisitions’

Mentor has said it is seeking to enter collaborations and acquisitions to bolster its product line.

After reporting an eight per cent drop in net operating income following the sale of its urology business, the Mentor’s chief executive officer described the company’s half-yearly results as “solid”, consider the company has been going through a period of restructuring.

The breast implant manufacturer recorded a sales increase of seven per cent, while research and development expenses increased.

In a webcast presentation following the release of the results, Joshua H Levine, president and chief executive of Mentor, is quoted by Reuters as saying that the company was considering making some strategic alliances.

He said: “Our focus in general is on things that will increase the scope and scale of our aesthetics footprint and basically looking at products that are on market or in late-stage clinical development.”

“We see significant opportunities for growth and are confident that our pure-play position in aesthetic medicine will drive long-term shareholder value,” he added.

The company has significant interests in the UK, employing personnel at its biopolymers manufacturing plant in Edinburgh, as well having offices in Newbury, Berkshire and Lancing in West Sussex.

© Adfero Ltd